Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

SCHOTT Announces Major Expansion of Pharmaceutical Packaging Manufacturing in Russia

Published: Monday, November 26, 2012
Last Updated: Monday, November 26, 2012
Bookmark and Share
Capacity to expand by more than 50 percent / Consistent investment strategy helps customers achieve growth and quality objectives.

SCHOTT Pharmaceutical Packaging continues to experience growth in Russia and now plans to increase the production capacities at its plant in in Zavolzhe by more than 50 percent. The manufacturer announced this move today at the Pharmtech trade fair in Moscow. “Expanding our presence in Russia represents an important strategic step for the benefit of our customers,” emphasizes Dr. Jürgen Sackhoff, responsible for the Pharmaceutical Systems division of SCHOTT AG. “We are seeing continued growth in demand for locally manufactured primary packaging that also meets all of the international standards for quality. This will result in shorter delivery routes and better export opportunities for our customers. In other words, by pursuing a consistent investment strategy, we will be helping our customers in the Russian pharmaceutical industry to achieve their own growth and quality objectives,” he adds.

The Russian pharmaceutical industry has experienced double-digit growth in recent years. State initiatives like the government’s “Pharma 2020” strategy that seeks to encourage local manufacturing of high-quality medications according to the GMP standard (“Good Manufacturing Practice”) will continue this development. SCHOTT became the first international manufacturer in Russia to open a new GMP-compliant pharmaceutical packaging plant in the spring of 2011 and it has been a great success. After all, the order situation has made it necessary to expand capacities earlier than expected. By setting up new production lines for vials and ampoules, SCHOTT has now demonstrated consistency in taking the next step toward continuing to offer its Russian customers shorter delivery times.

“Thanks to our many years of experience and high international standards for quality, SCHOTT is the right partner for the ambitious and growing Russian pharmaceutical industry,” Sackhoff adds. Here, he is referring to the growing quality requirements of the Russian pharmaceutical industry. “GMP will be required by law for all companies that manufacture in Russia starting in 2014 and SCHOTT has the necessary know-how on helping its customers to establish GMP-certified manufacturing thanks to its 125 years of experience and global manufacturing network,” Sackhoff concludes.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Biomolecular Manufacturing ‘On-the-Go’
Wyss Institute team unveils a low-cost, portable method to manufacture biomolecules for a wide range of vaccines, other therapies as well as diagnostics.
Molecular Switch Aids Immune Therapy
Researchers identify strategy to maximise effectiveness of immune therapy through molecular switch controlling immune suppression.
Novavax RSV F Vaccine Fails Phase 3 Trial
Novavax announces topline RSV F Vaccine data from two clinical trials in older adults.
GSK’s Shingles Vaccine Candidate Shows High Efficacy
The vaccine candidate showed high efficacy against shingles and its complications in adults aged 70yrs+ in phase III study.
Eisai Establishes AiM Institute
The Andover innovative Medicines (AiM) Institute will develop innovative precision medicines for hard-to-treat conditions.
Antibodies that Target Holes in HIV's Defence Identified
Scientists suggest 'holes' in HIV sugar sheild can be targeted by antibodies.
Discovery Could Yield Improved Flu Vaccines
Researchers have discovered a type of immune antibody that can evolve to combat a number of infuenza virus strains.
First Accurate Simulation of a Virus Invading a Cell
For the first time, scientists know what happens to a virus’ shape when it invades a host cell.Understanding how the virus shape specifically changes could lead to more effective anti-viral therapies.
Developing a Vaccine for Sexually Transmitted and Insect-Borne Zika Infections
Prokarium announce the beginning of a programme to develop an oral vaccine against Zika infection.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!